Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself
Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.
You may also be interested in...
AbbVie CEO Richard Gonzalez defended the roughly $21 billion purchase price it offered to pay for Pharmacyclics, citing bullish long-term sales projections for Imbruvica driven by indication expansion.
Company moves fast to test pembrolizumab in head and neck cancer, among other new frontier tumor types. The firm has reorganized its oncology business to prepare for launch in melanoma, which will be a critical test of the company’s ambitions to become a cancer powerhouse.
At an R&D day presentation in Boston, Merck executives claimed R&D restructuring is beginning to bear fruit, presenting the pharma with a host of near-term launch possibilities. Outside of cancer immunotherapy, Merck has obtained or anticipates approvals in cardiovascular health, insomnia, diabetes, hepatitis C, osteoporosis, and allergies.